

Please try another search
For the three months ended 31 March 2022, Kura Oncology Inc revenues was not reported. Net loss increased 6% to $32.5M. Higher net loss reflects Payroll related expenses increase of 56% to $8.2M (expense), Share-based compensation increase of 79% to $2.5M (expense), General and administrative - Balancing increase of 14% to $7.7M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.46 to -$0.49.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -32.78 | -33.04 | -33.68 | -33.85 |
Net Income | -32.45 | -32.74 | -33.37 | -33.66 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 498.58 | 534.05 | 561.14 | 584.89 |
Total Liabilities | 22.34 | 27.44 | 27.39 | 26.34 |
Total Equity | 476.25 | 506.61 | 533.76 | 558.55 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -32.18 | -104.55 | -81.19 | -56.59 |
Cash From Investing Activities | -24.96 | -126.83 | -200.9 | -223.44 |
Cash From Financing Activities | 0.3 | -3.44 | -4.23 | -6.49 |
Net Change in Cash | -56.84 | -234.82 | -286.31 | -286.52 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review